-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Biegie Lee
Senior Vice President,
Chief Information Officer
Chief Information Officer
Mr. Lee is senior vice president and chief information officer with responsibility for leading the information technology operations, network infrastructure, enterprise applications, project management, and cybersecurity programs. He works closely with senior management to align IT investments with corporate strategy and business objectives. He joined Novavax in 2017 as senior director of IT with more than 20 years of IT experience, the vast majority of which has been in the life sciences industry. Prior to joining Novavax, he served as vice president of cloud solutions at IPDS, Inc., an information technology services company, where he led development and implementation of the cloud solutions portfolio. Mr. Lee previously held positions of increasing responsibility at Human Genome Sciences (HGS) leading up to its acquisition by GlaxoSmithKline (GSK). He led the global IT integration and successfully completed the disposition of all IT assets during the transition of HGS into GSK.